title: Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases.
abstract: Advanced gastric cancer (GC) has been recognized as lethal disease when peritoneal metastases (PM) occurred. There is no standard treatment for advanced GC with PM. Until 1980s, the therapeutic arena for these patients had remained stagnant, with no therapeutic approach having shown a survival gain in GC with PM. However, cytoreductive surgery (CRS) with peritonectomy procedures and intraperitoneal chemotherapy (IPC) promising new combined therapeutic approach to achieve disease control for GC with PM. The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival (OS). This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.
authors.affiliation: 1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
authors.forename: Emel
authors.initials: E
authors.lastname: Canbay
authors.affiliation: 1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yonemura
authors.affiliation: 1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
authors.forename: Bjorn
authors.initials: B
authors.lastname: Brucher
authors.affiliation: 1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
authors.forename: Seung Hyuk
authors.initials: SH
authors.lastname: Baik
authors.affiliation: 1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
authors.forename: Paul H
authors.initials: PH
authors.lastname: Sugarbaker
keywords: Gastric cancer (GC); cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (IPC); intraperitoneal and systemic induction chemotherapy; peritoneal carcinomatosis